Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023 2024
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

COVID-19 vaccination in Hungary is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

Vaccination program

Around 20.13% of the Hungarian citizens (based on the 2011 census ^[1][2] and the official vaccination statistics) have received, at least, one anti-COVID-19 injection, since 28 March 2021.

Background

Reports in March 2021 stated that Hungary was the first country in the EU to "begin using China's Sinopharm BIBP and Russia's Sputnik V vaccines, even as polling showed that public trust in non-EU approved vaccines was low".^[3] The European Commission's Vaccine Passport plan excluded the Sputnik and Sinopharm products because they were not "EU authorized vaccines". One suggestion to resolve that issue was that "Russian and Chinese vaccine producers submit their products to the EMA for testing and authorization".^[4] At the end of March 2021, Hungary also granted emergency use licenses to two more vaccines, CanSino (from China) and Covishield (the AstraZeneca vaccine produced by the Serum Institute of India).^[5]

Vaccines on order

Vaccine	Approval	Deployment
Oxford–AstraZeneca	Yes	Yes
Sinopharm BIBP	Yes	Yes
Pfizer–BioNTech	Yes	Yes
Moderna	Yes	Yes
Janssen	Yes	Yes
Sputnik V	Yes	Yes
Convidecia	Yes	No
Novavax	Yes	No
Sanofi–GSK	Pending	No
CureVac	Pending	No
Valneva	Pending	No

Government response

On 17 March 2020, the Surgeon General announced that the National Safety Laboratory of National Health Security Center had successfully isolated COVID-19 from a Hungarian patient's sample, which it could use for the research and development of a new Hungarian vaccine.^[6][7] A consortium founded by the Department of Immunology at the Faculty of Sciences of Eötvös Loránd University, the Institute of Biology at the Science Faculty of the University of Pécs, Richter Gedeon and ImmunoGenes is involved in international biotechnological developments.^[8][9] Imre Kacskovics, leader of Immunology Department of ELTE, said the product currently in the first phase of development won't be a vaccine, but provide passive immunity. It will not prepare the body to fight against the virus.^[10] Some days after the successful isolation, the Bioinformatic Research Team of Szentágothay János Research Center at the University of Pécs and the university's virologists made the genome of the new SARS-CoV-2 human coronavirus available in Hungary.^[11][12]